Roundtable
Advertisement
The panel shares interesting clinical trial data in development, including CONTACT-03, TiNivo-2, and more.
The panel discusses triplet combinations in development for RCC.
The panel discusses the disappointing results of the COSMIC-313 trial.
The panel discusses exciting ongoing clinical trials, including 304, TiNivo-2, PDIGREE, and more.
The panel shares how they treat frontline papillary kidney cancer.
The panel discusses treatment-related toxicities and when to consider stopping treatment.
The panel considers how to treat in the adjuvant setting following prior IO/IO or IO/TKI treatment.
The panel compares three treatment regimens.
The panel debates the "phenomenon" of rechallenging treatment in subsequent treatment lines.
The panel discusses the CheckMate 8Y8 clinical trial.
The panel discusses the challenge of second-line RCC treatment options and how to sequence therapy.
The panel discusses outcomes from the CheckMate-9ER trial and addresses the importance depth of response.
The panel compares three TKI/IO treatment combinations.
The panel discusses considerations for treatment choice in patients with poor- and intermediate-risk disease.
The panel discusses which patients in their practices would be candidates for ipilimumab/nivolumab combination.
The panel discusses monotherapy treatment for RCC.
The panel discusses how they each approach debulking nephrectomy in their RCC patients.
A panel discusses 4 frontline RCC treatment options.
Dr. Rini is joined by a panel of RCC experts to discuss patient characteristics that impact treatment selection.
Panel experts discuss PSMA-targeting agents currently being assessed, including PSMA-I&T-Lutetium-177.
Advertisement
670 Madison Ave.
Manalapan, NJ 07726